MedTrace Logo

Azilect® In Wearing-Off (AIWO)

NCT02384512 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 261

Last updated 2023-04-12

No results posted yet for this study

Summary

End-of-dose fluctuations e. g. wearing-off are defined as a recurrence of motor and non-motor Parkinson's Disease (PD) symptoms that precedes a scheduled dose and improves with the next dose of anti-parkinsonian medication. Azilect® is approved and recommended for therapy of wearing-off-/End-of-dose fluctuations and improves motor fluctuations significantly in combination therapy with L-dopa and other parkinsonian medication.

Conditions

Interventions

DRUG

Azilect®

AZILECT® 1mg Tablets

Sponsors & Collaborators

  • Anfomed GmbH

    collaborator INDUSTRY

  • Teva Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Medical Expert, MD · Paracelsus Elena Klinik

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-12-31
Completion
2015-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02384512 on ClinicalTrials.gov